Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
ORGANIZATION
Pharma Hails Expert Panel Report, Looks for Govt Leadership to Execute Reforms
Major pharma trade organizations on June 6 welcomed a draft report broadly adopted by a key health ministry expert panel for comprehensive measures to ensure rapid and stable drug supplies, expressing their expectations for concrete steps to follow. In its…
To read the full story
Related Article
ORGANIZATION
- PhRMA HTA Taskforce Warns CEA Expansion Will Accelerate Drug Loss in Japan
April 18, 2025
- JPMA Sets Up Response Team to Collect Info on US Tariff Measures
April 18, 2025
- Medical Advocacy Group Condemns Plan to Remove Coverage for OTC-Like Drugs
April 17, 2025
- JGA to Release Interim Report on Industry Revamp in June: President
April 14, 2025
- Contradictions in Drug Pricing System Can No Longer Be Overlooked: Ex-Bureaucrat
April 10, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…